Bayer stock gets U.S. launch path for first Factor XIa drug
Published on 11/11/2026 at 18:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLaunch timing and trial evidence
- Bayer expects Sunharbo shipments to begin in mid-to-late November in the United States.
- The OCEANIC-STROKE trial enrolled 12,327 patients and showed a 26 percent reduction in ischemic stroke versus placebo.
- The regulatory opportunity is limited to defined post-stroke and high-risk TIA patients, while applications in Europe and Japan remain under review.
Bayer's U.S. approval of Sunharbo has moved from regulatory milestone to launch execution. In a release dated November 10, Bayer said it expects shipments of the asundexian tablets to begin in mid-to-late November, with hospitals and pharmacies able to order the medicine shortly afterward. The company made the statement after the U.S. Food and Drug Administration approved the treatment on November 9. Bayer described Sunharbo as the first approved Factor XIa inhibitor in the United States.
New launch detail raises execution stakes
The launch schedule gives investors a near-term test for Bayer's Pharmaceuticals division. Approval opens access to a new treatment class, but the commercial contribution will depend on prescription uptake, reimbursement and the pace of expansion beyond the initial U.S. indication. Bayer said Sunharbo is indicated with antiplatelet therapy for adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
Trial results and safety profile
The Phase 3 OCEANIC-STROKE study randomized 12,327 patients. Bayer reported that ischemic stroke occurred in 6.2 percent of patients receiving Sunharbo compared with 8.4 percent in the placebo group, a relative reduction of 26 percent. Major bleeding rates were similar, although gastrointestinal bleeding was higher with Sunharbo and the release reported greater major-bleeding rates among patients older than 75 and during the first 90 days of treatment.
China approved Sunharbo on October 26, while Bayer said applications in Europe and Japan were still under review as of November. The label does not cover stroke prevention in atrial fibrillation, keeping the initial commercial opportunity focused on a defined patient group.
Stock trades below the Xetra close
Bayer stock traded at 56.68 euros on Lang & Schwarz at 18:30 CET on Wednesday, November 11, 0.14 percent below the Xetra close of Wednesday, November 11. The comparison uses the Xetra close of 56.76 euros and does not establish a causal link to the approval.
Bayer company and stock facts
- Company: Bayer AG
- ISIN: DE000BAY0017
- Xetra ticker: BAYN.DE
- Lang & Schwarz price: 56.68 euros at 18:30 CET on November 11, 2026
- Change versus Xetra: 0.14 percent below the November 11, 2026 close of 56.76 euros
The DAX provides the broader German market backdrop for Bayer stock.
